Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 19

1.

Off‑target effect of imatinib and nilotinib on human vitamin D3 metabolism.

Kroschwald L, Suttorp M, Tauer JT, Zimmermann N, Günther C, Bauer A.

Mol Med Rep. 2018 Jan;17(1):1382-1388. doi: 10.3892/mmr.2017.7952. Epub 2017 Nov 3.

PMID:
29115640
2.

Metabolic phenotype in the mouse model of osteogenesis imperfecta.

Boraschi-Diaz I, Tauer JT, El-Rifai O, Guillemette D, Lefebvre G, Rauch F, Ferron M, Komarova SV.

J Endocrinol. 2017 Sep;234(3):279-289. doi: 10.1530/JOE-17-0335. Epub 2017 Jul 17.

PMID:
28716975
3.

Response dynamics of pediatric patients with chronic myeloid leukemia on imatinib therapy.

Proschmann R, Baldow C, Rothe T, Suttorp M, Thiede C, Tauer JT, Müller MC, Hochhaus A, Roeder I, Glauche I.

Haematologica. 2017 Feb;102(2):e39-e42. doi: 10.3324/haematol.2016.154138. Epub 2016 Nov 17. No abstract available.

4.

Impact of long-term exposure to the tyrosine kinase inhibitor imatinib on the skeleton of growing rats.

Tauer JT, Hofbauer LC, Jung R, Gerdes S, Glauche I, Erben RG, Suttorp M.

PLoS One. 2015 Jun 24;10(6):e0131192. doi: 10.1371/journal.pone.0131192. eCollection 2015.

5.

Can prognostic scoring systems for chronic myeloid leukemia as established in adults be applied to pediatric patients?

Gurrea Salas D, Glauche I, Tauer JT, Thiede C, Suttorp M.

Ann Hematol. 2015 Aug;94(8):1363-71. doi: 10.1007/s00277-015-2367-2. Epub 2015 Apr 19.

PMID:
25894600
6.

Inhibitory effects of imatinib on vitamin D₃ synthesis in human keratinocytes.

Mehlig LM, Garve C, Tauer JT, Suttorp M, Bauer A.

Mol Med Rep. 2015 Apr;11(4):3143-7. doi: 10.3892/mmr.2014.3074. Epub 2014 Dec 10.

PMID:
25501030
7.

Long-term imatinib treatment does not cause testicular toxicity in male adolescents with chronic myeloid leukemia and in a juvenile rat model.

Tauer JT, Ulmer A, Glauche I, Jung R, Suttorp M.

Klin Padiatr. 2014 May;226(3):169-74. doi: 10.1055/s-0034-1372643. Epub 2014 May 12.

PMID:
24819387
8.

Sustained complete molecular remission after imatinib discontinuation in children with chronic myeloid leukemia.

Moser O, Krumbholz M, Thiede C, Tauer JT, Janz I, Lauten M, Dilloo D, Metzler M, Suttorp M.

Pediatr Blood Cancer. 2014 Nov;61(11):2080-2. doi: 10.1002/pbc.25090. Epub 2014 May 9.

PMID:
24810322
9.

DNA copy number alterations mark disease progression in paediatric chronic myeloid leukaemia.

van der Sligte NE, Krumbholz M, Pastorczak A, Scheijen B, Tauer JT, Nowasz C, Sonneveld E, de Bock GH, Meeuwsen-de Boer TG, van Reijmersdal S, Kuiper RP, Bradtke J, Metzler M, Suttorp M, de Bont ES, van Leeuwen FN.

Br J Haematol. 2014 Jul;166(2):250-3. doi: 10.1111/bjh.12850. Epub 2014 Mar 27. Erratum in: Br J Haematol. 2014 Nov;167(4):584.

PMID:
24673583
10.

Micro-osmotic pumps for continuous release of the tyrosine kinase inhibitor bosutinib in juvenile rats and its impact on bone growth.

Tauer JT, Hofbauer LC, Jung R, Erben RG, Suttorp M.

Med Sci Monit Basic Res. 2013 Nov 4;19:274-8.

11.

Changes in bone metabolic parameters in children with chronic myeloid leukemia on imatinib treatment.

Jaeger BA, Tauer JT, Ulmer A, Kuhlisch E, Roth HJ, Suttorp M.

Med Sci Monit. 2012 Dec;18(12):CR721-8.

12.

Identification of the genomic BCR-ABL1 fusion sequence from blood specimen stored on filter paper.

Karl M, Krumbholz M, Tauer JT, Jacobs U, Metzler M, Suttorp M.

Leuk Res. 2013 Jan;37(1):117-9. doi: 10.1016/j.leukres.2012.10.007. Epub 2012 Nov 3.

PMID:
23127356
13.

Desmopressin testing in haemophilia A patients and carriers: results of a multi centre survey.

Knöfler R, Koscielny J, Tauer JT, Huhn B, Gneuss A, Kuhlisch E, Hofmann A, Petros S, Aumann V, Franke D, Kentouche K, Syrbe G, Seeger K, Haberland H, Klamroth R.

Hamostaseologie. 2012;32(4):271-5. doi: 10.5482/HAMO-12-06-0012. Epub 2012 Sep 3.

PMID:
22940861
14.

Genomic BCR-ABL1 breakpoints in pediatric chronic myeloid leukemia.

Krumbholz M, Karl M, Tauer JT, Thiede C, Rascher W, Suttorp M, Metzler M.

Genes Chromosomes Cancer. 2012 Nov;51(11):1045-53. doi: 10.1002/gcc.21989. Epub 2012 Aug 9.

PMID:
22887688
15.

Management of chronic myeloid leukemia in childhood.

Suttorp M, Eckardt L, Tauer JT, Millot F.

Curr Hematol Malig Rep. 2012 Jun;7(2):116-24. doi: 10.1007/s11899-012-0113-6. Review.

PMID:
22395816
16.

Therapy refractory menorrhagia as first manifestation of Hermansky-Pudlak syndrome.

Lohse J, Gehrisch S, Tauer JT, Knöfler R.

Hamostaseologie. 2011 Nov;31 Suppl 1:S61-3.

PMID:
22057877
17.

Evaluation of desmopressin effect on primary haemostasis in pediatric patients with aspirin-like defect as hereditary thrombocytopathy.

Tauer JT, Gneuss A, Lohse JE, Jürgens T, Knöfler R.

Klin Padiatr. 2011 May;223(3):169-72. doi: 10.1055/s-0031-1275347. Epub 2011 Apr 20.

PMID:
21509710
18.

Investigations of Platelet Function in Whole Blood with BAPA as Anticoagulant.

Tauer JT, Lohse J, König S, Knöfler R.

Transfus Med Hemother. 2010;37(5):284-288. Epub 2010 Sep 15.

19.

Impact of the type of the BCR-ABL fusion transcript on the molecular response in pediatric patients with chronic myeloid leukemia.

Suttorp M, Thiede C, Tauer JT, Range U, Schlegelberger B, von Neuhoff N.

Haematologica. 2010 May;95(5):852-3. doi: 10.3324/haematol.2009.019224. Epub 2010 Feb 9. No abstract available.

Supplemental Content

Loading ...
Support Center